Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

15.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
15.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Predictive Value of Baseline Left Ventricular Global Longitudinal Strain for Cardiac Dysfunction in Patients with Moderate to High Risk of Cancer Therapy-Related Cardiovascular Toxicity.

Pharmaceuticals (Basel, Switzerland)·2025
Same author

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.

Blood·2025
Same author

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same author

Microbial and Metabolic Gut Profiling across Seven Malignancies Identifies Fecal <i>Faecalibacillus intestinalis</i> and Formic Acid as Commonly Altered in Cancer Patients.

International journal of molecular sciences·2024
Same author

Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma.

Blood·2024

Related Experiment Video

Updated: Jan 4, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.6K

Aggressive B-cell lymphoma: chasing the target.

Jan Walewski1

  • 1Lymphoid Malignancy, Maria Sklodowska-Curie Institute - Oncology Center, Warszawa, Poland jan.walewski@coi.pl.

Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research
|November 2, 2019
PubMed
Summary

Diffuse large B-cell lymphoma (DLBCL) classification has evolved beyond cell of origin (COO) subtypes. Advanced molecular profiling offers new frameworks for improved treatment strategies in aggressive lymphomas.

Keywords:
drugsinvestigationalpharmacogenetics

More Related Videos

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.3K
Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

13.1K

Related Experiment Videos

Last Updated: Jan 4, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.6K
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.3K
Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

13.1K

Area of Science:

  • Molecular biology
  • Hematology
  • Oncology

Background:

  • Cell of origin (COO) classification (activated B-cell like and germinal center B-cell like) of diffuse large B-cell lymphoma (DLBCL) emerged ~20 years ago.
  • COO subtypes were thought to influence DLBCL biology, treatment response, and prognosis.
  • Standard R-CHOP immunochemotherapy cures ~60% of DLBCL patients, with variable efficacy based on prognostic factors.

Purpose of the Study:

  • To discuss the evolution of DLBCL classification beyond COO.
  • To highlight recent advancements in molecular profiling for B-cell lymphomas.
  • To propose a framework for future clinical trial design based on advanced molecular pathogenesis.

Main Methods:

  • Gene expression profiling for initial COO classification.
  • Analysis of targeted agents added to R-CHOP in clinical trials.
  • Application of advanced molecular techniques for lymphoma classification.

Main Results:

  • Randomized trials of targeted agents added to R-CHOP did not demonstrate significant benefit.
  • Recent studies utilize advanced molecular techniques to classify B-cell lymphomas beyond COO.
  • These new classifications correlate with clinical outcomes.

Conclusions:

  • Existing COO classification and R-CHOP therapy have limitations for high-risk DLBCL.
  • Advanced molecular pathogenesis provides a basis for actionable classifications.
  • Future clinical trials should incorporate these advanced molecular insights for improved DLBCL treatment.